Which Biotech Stocks would profit from New ‘Nu’ COVID Strain
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Cully : Pfizer and Moderna. It will be easy to alter their vaccines to a new strain. The regulatory hurdles are the slow part.
Feleshia : Don't forget BioNTech ($BNTX) - they share 50% of revenue with Pfizer for Comirnaty. Also they were the ones who made the vaccine (Pfizer helped with testing, and distribution). Also 9 P/E ratio
坏蛋宝贝 : 乱tag